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Abstract
Purpose To test the performances of native and tumour to liver ratio (TLR) radiomic features extracted from pre-treatment
2-[18F] fluoro-2-deoxy-D-glucose ([18F]FDG) PET/CT and combined with machine learning (ML) for predicting cancer recur-
rence in patients with locally advanced cervical cancer (LACC).
Methods One hundred fifty-eight patients with LACC frommultiple centers were retrospectively included in the study. Tumours
were segmented using the Fuzzy Local Adaptive Bayesian (FLAB) algorithm. Radiomic features were extracted from the
tumours and from regions drawn over the normal liver. Cox proportional hazard model was used to test statistical significance
of clinical and radiomic features. Fivefold cross validation was used to tune the number of features. Seven different feature
selection methods and four classifiers were tested. The models with the selected features were trained using bootstrapping and
tested in data from each scanner independently. Reproducibility of radiomics features, clinical data added value and effect of
ComBat-based harmonisation were evaluated across scanners.
Results After a median follow-up of 23 months, 29% of the patients recurred. No individual radiomic or clinical features were
significantly associated with cancer recurrence. The best model was obtained using 10 TLR features combined with clinical
information. The area under the curve (AUC), F1-score, precision and recall were respectively 0.78 (0.67–0.88), 0.49 (0.25–
0.67), 0.42 (0.25–0.60) and 0.63 (0.20–0.80). ComBat did not improve the predictive performance of the best models. Both the
TLR and the native models performance varied across scanners used in the test set.
Conclusion [18F]FDG PET radiomic features combined with ML add relevant information to the standard clinical parameters in
terms of LACC patient’s outcome but remain subject to variability across PET/CT devices.
This article is part of the Topical Collection onAdvanced Image Analyses
(Radiomics and Artificial Intelligence).
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Introduction
Cervical cancer is the fourth most common cancer in women
[1]. Currently, in clinical routine, the disease prognosis is
based upon the FIGO/TNM staging system, with a particular
emphasis on the lymph node involvement [2, 3]. Despite im-
proved outcome, thanks to the introduction of concurrent che-
moradiotherapy, the overall recurrence rate in patients with
locally advanced cervical cancer (LACC) is 35%, and the
median survival after recurrence is 10–12 months [2, 3].
Improving the patient risk stratification in order to adapt the
treatment or surveillance schemes in high-risk patients would
fulfil an unmet clinical need.
2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron
emission tomography combined with computed tomography
(PET/CT) imaging plays an important role in treatment strat-
ification in oncology. In cervical cancer, parameters such as
the standard uptake value (SUV), metabolic tumour volume
(MTV) or total lesion glycolysis (TLG) have been proposed as
prognostic factors, although none has been integrated in the
clinical decision algorithms [4]. Recently, there has been an
increased interest in radiomics i.e. the characterisation of tu-
mour phenotypes via the extraction of high-dimensional quan-
titative features from medical images, with the aim to support
clinical decision-making [5–7]. Radiomic features have
shown to predict treatment outcome in several cancer diseases
including cervical cancer, and using various imaging modali-
ties [8–11]. However, most of radiomic features show high
sensitivity to multiple factors, including the scanner manufac-
turer and specific properties, acquisition protocols and the
reconstruction algorithm and settings of each clinical center
[12–18]. Radiomics have increasingly been combined with
machine learning (ML) techniques in order to predict a spe-
cific clinical outcome [8, 10, 11, 19–26].
In this study, we first extracted radiomic features from
multi-center/multi-scanner [18F]FDG PET images of cervical
cancer and evaluated the performance of different classifiers
combined with different feature selection (FS) methods to
predict DFS. We hypothesised that a PET-based radiomics
signature would have a significant prognostic value, higher
or complementary to standard clinical parameters. We then
evaluated the predictive value of tumour to liver ratios
(TLR) of radiomic features [27]. The liver uptake is indeed
quite homogeneous and reproducible [28], and we
hypothesised that this may reduce the variability of uptake
within the different patients and across centres.We also inves-
tigated the effect of several pre-processing steps of radiomics
workflow applied before FS, including intensity discretisation
scheme for textural features, the use of ComBat method for
features harmonisation and image voxel size resampling, as
well as the added value of clinical data and ComBat
harmonisation after FS. Finally, we evaluated the performance
of the trained models on data from each individual and exter-
nal validation scanner, and we compared our radiomic signa-
ture with those previously developed by other research group
[8].
Materials and methods
Patients and treatment information
One hundred and fifty-eight patients with LACC imaged be-
tween 2010 and 2016 were included in this retrospective
study. All patients were treated with platinum-based chemo-
therapy and a combination of external radiotherapy (EBRT)
(3D or not) and brachytherapy (BT), with a total dose of
85 Gy. Various regimens were applied depending on the
treating Center: EBRT 45–50 Gy and pulse-dose rate brachy-
therapy (PDR) 35–40 Gy (n = 77); EBRT 45–50 Gy and high-
dose brachytherapy (HDR) 4 × 6 or 7 Gy (n = 18); EBRT
60 Gy and PDR-BT 25 Gy (n = 1); EBRT 60 Gy and HDR-
BT 3 × 7 Gy (n = 1); EBRT in addition to pulse-dose rate
brachytherapy (PDR) with total dose of 60 to 70 Gy (n =
45). A complementary boost centered on the tumour was also
given to 50 patients. A detailed description of patient clinical
characteristics is given in Table 1. All patients had histologi-
cally proven cervical cancer and a median follow-up of
23 months (range: 4–84).
PET/CT imaging
PET/CT studies were performed with 3 types of scanners. In
the CHU of Liège, 89 studies were acquired using a Philips
Gemini TF or BB (scanner A), and in the CHU of Brest and
ICO St Herblain 17 and 34, respectively, were acquired using
a Siemens Biograph mCT (scanner B). In addition, 18 studies
performed with a General Electric Discovery ST (scanner C)
at the McGill University Health Center were used as an exter-
nal validation set. A mean activity of 306 MBq of [18F]FDG
was injected before image acquisition with a mean uptake
time of 66 min. The acquisition and reconstruction protocols
are described in Table 1 of the supplementary data A.
Radiomics workflow
The radiomics workflow usually consists of image acquisition
or collection, image pre-processing (such as image interpola-
tion, segmentation or intensity discretisation in the case of
textures), extraction of the radiomic features and finally
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modelling [29].We describe in the next sections the radiomics
workflow used in this work.
Images interpolation
PET images from scanners B and C, were interpolated in order
to study the effect of image interpolation in the predictive
performance of radiomics. We up-sampled or down-sampled
the images using a linear method, so that all datasets had
isotropic voxels of 4 mm3. Interpolation was done using a
research toolbox (Oncoradiomics SA, Liège, Belgium).
Segmentation
The 3D primary tumour volumes were segmented from the
[18F]FDG PET images using the semi-automatic Fuzzy Local
Adaptive Bayesian (FLAB) algorithm with 2 classes [30]. The
median volume of the segmented lesions was 28.6 cm3 (range:
2.4–181.2 cm3). In addition, regions of 20 cm3 in the liver
were manually drawn in order to investigate the predictive
value of TLR radiomic features, as explained below. Those
segmentations were reviewed and edited if needed by one
nuclear medicine physician with 9 years of experience in clin-
ical PET/CT. No volume cut-off value was applied for patient
inclusion in this study.
Radiomic features and intensity discretisation
Two hundred and fifteen features were extracted from the
segmented volumes using the Oncoradiomics research tool-
box. These features included first-order grey level statistics,
geometry, fractals, texture matrix-based features and others.
The detailed description of the features can be found in sup-
plementary data B. For those standardised by the IBSI
(Imaging biomarkers standardisation initiative), the
implementation follows IBSI benchmark. We also studied
the ratio of the features’ values calculated in the tumour and
in the liver (TLR), except for the shape features. In addition to
the radiomic features, data also included 4 clinical parameters
i.e. FIGO stage (IB to IVA), histological types (squamous cell
carcinoma (SCC) or not), age and presence of lymph node
(LN) metastasis.
For the calculation of the texture matrix-based features, the
intensities needed to be discretised. Image intensities were
discretised using two different methods according to IBSI
recommendations: fixed bin number (FBN, using 32 and 64
bins) and fixed bin width (FBW, with 4 different widths of
0.05, 0.1, 0.2 and 0.5 SUV) [29]. There was no missing data
for any patient.
ComBat harmonisation
ComBat is a batch adjustment method initially developed for
genomics data [31, 32]. It has also been used in PET and CT
studies to correct the center variability of radiomic features
[33, 34]. In our work, we intended to use ComBat
harmonisation to correct the effect of multi scanner acquisition
and to test whether it could improve the predictive perfor-
mance of predictive models based on radiomic features. First
ComBat was applied with the non-parametric version, before
FS. Since there was no significant difference in clinical char-
acteristics of patients across centers, we did not use the covar-
iate matrix modelling. Second, in a separate set of experi-
ments, the best performance models were also retrained using
ComBat harmonisation after FS.
Statistical analysis
Clinical and treatment data from the different scanners were
compared using chi square test for categorical data (FIGO,
Table 1 Patient’s characteristics
CHU Liège (Scanner A) CHU Brest and ICO
St Herbain (Scanner B)
Total CHU Mcgill (Scanner C)
Number of patients 89 51 140 18
Age (median and range in years) 50 (23–76) 52 (23–82) 51 (23–82) 50 (28–86)
FIGO (%)
IB1-IB2 18% 12% 16% 6%
IIA-IIB 66% 58% 64% 56%
IIIA-IIIB 12% 18% 14% 33%
IVA 3% 12% 6% 6%
Histology (% of SCC)
87% 82% 85% 89%
LN metastasis
% of patients 19% 16% 18% 28%
Recurrence (%) 21% 35% 26% 50%
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histology, presence of LN metastasis, type of EBRT i.e. 3D or
not, complementary boost centered on the tumour and combi-
nation of EBRT/BT) to test the null hypothesis that the distri-
bution of each of the parameters categories between the scan-
ners were independent. For continuous data (age), we used a
one-way ANOVA to test whether the difference in means
differs or not. To predict DFS, a univariate Cox proportional
hazard model was first applied to the clinical, treatment,
radiomics and TLR radiomics data for each discretisation
method. To this end, we separated our data into training and
testing sets (80% and 20% of the data from each scanner,
respectively). Training data was standardisedwith z-score nor-
malisation before performing the Cox regression. The univar-
iate Cox model was used to test the statistical significance (P
value < = 0.05) of the features. Pearson correlation was com-
puted between pairs of features. In case the correlation was
higher than 0.9, the feature which was most correlated with all
the others was removed. The Holm-Bonferroni correction
method was used to correct for multiple hypothesis testing
[35]. A multivariate Cox proportional hazard model was per-
formedwith the remaining features. Finally, the Youden index
was used for extracting a threshold for the receiver operating
characteristic (ROC) curve of the train data of each individual
significant feature, clinical features and tumour volume (TV).
Afterwards, the thresholds were used to plot Kaplan-Meier
curves and evaluate individual features performance using
recall, precision, and F1-score metrics. Differences in survival
were evaluated using the log-rank test. In addition to the Cox
model, we also evaluated whether combining different FS and
ML classifiers methods was able to find a radiomics signature
to predict DFS. For that purpose, we first dichotomised DFS
into a binary endpoint i.e. recurrence or no recurrence, inde-
pendently of the time of the recurrence. Next, we tested a
different set of models, which differs in (i) the features type
i.e. original radiomics (OR) or TLR radiomics, (ii) the pre-
processing of the PET images i.e. with or without interpola-
tion, (iii) the pre-processing of the features i.e. with or without
ComBat harmonisation and intensity discretisation scheme,
(iv) the FS and ML classifier method and (v) the metric used
to optimise the number of features used in the model.
Additionally, we also investigated the effect of adding clinical
data before FS.
We tested 7 different FS methods: (1)- Accuracy decrease
obtained from the embedded FS of the random forest (RF)
classifier; (2)- Gini impurity decrease obtained from the em-
bedded FS of the RF classifier; (3)- forward FS using maxi-
mum relevance minimum redundancy (MRMR) method with
Pearson correlation; (4)- backward FS using MRMR with
Pearson correlation; (5)- forward FS using MRMR with
Spearman correlation; (6)- backward FS using MRMR with
Spearman correlation and (7)- forward MRMR based on the
mutual information (MI). We also used 4 ML classifiers: RF,
support vector machine (SVM) with radial kernel, Naïve
Bayes (NB) and a logistic regression (LR) [36–38]. The train-
ing data was used to tune the number of features selected by
each FS method, which were limited to 10 in order to avoid
overfitting. We used fivefold cross validation in our training
data and chose the number of features to be used according to
the best mean fold area under the curve (AUC) value, F-score
(with Beta 1 and 2) and AUC of precision recall curve
(AUCpr). Patients who recur were oversampled using the ran-
dom oversampling method in the training data to help in the
learning process [39]. We repeated this procedure for each of
the models. We used for each classifier the default
hyperparameters values in their respective R packages.
Finally, for each of the different models with distinct selected
features, all training data were bootstrapped with 1000 repeti-
tions, in order to get confidence intervals for each perfor-
mance metric, and tested on one test set independent of
model/feature selection training set. We measured AUC, F1-
score and F2-score, precision, recall, AUCpr and its corre-
sponding percentile confidence intervals of the distinct
models. We considered as best model the one with higher
bootstrap F1-score values. A 0.5 probability threshold of the
recurrence event was used to plot Kaplan-Meier curves.
Survival curves were compared with the log-rank test.
Delong test was used to compare AUC and a binomial test
to compare precision of the best OR and TLR models [40].
The best performance models were retrained and retested
adding clinical features and correcting multi-scanner variabil-
ity using ComBat harmonisation after FS in order to investi-
gate whether they could improve the models’ predictive abil-
ity. To decrease the overfitting risk of our models, we
randomised the outcome of the test set and evaluate our model
performance. By randomising the outcome, we expect to get
an AUC close to 0.5.
To test the dependency of prediction performance on data
from different scanners, we replaced the test data belonging
from all scanners with data from all the different scanners inde-
pendently. We also validated our model in the data from scan-
ner C, which was never seen in the training process. Statistical
and ML analyses were performed using R software (Fig. 1).
Finally, we compared our models with the 3 statistical sig-
nificant radiomic signatures (G1, G2 and G3) developed by
Altazi et al. [8] for predicting local regional recurrence (LRR).
We tested these radiomic signatures in the mix test set i.e. test
set from scanner A + B, using the AUC. Predictor assessments
were blinded for outcome or other predictors in all steps of this
work.
Results
After a median follow-up of 23 months, 29% of the patients
recurred. There was no difference between the clinical char-
acteristics of the 3 cohorts (P value: FIGO = 0.1084, presence
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of LN metastasis = 0.5302, histology = 0.7691 and age =
0.7205).
With a cox proportional hazard model, clinical features,
treatment scheme, TV, SUVmax, MTV and TLG at any thresh-
old, were not significantly associated with DFS in univariate
analysis (Table 2). The significant features in the univariate
and multivariate analyses are listed in Table 3. As features
were standardised before performing the Cox regression, the
hazard ratio units correspond to standard deviations of the
different covariates. The most significant features were textur-
al (GLDZM and GLSZM). Figure 2 shows the Kaplan-Meier
curves for each of the significant individual features. The
threshold for each feature was defined through the Youden
Index of the feature ROC curve in the training data.
GLSZM_HILAE_0.5 (TLR) was the only feature providing
statistically different stratification between the two Kaplan-
Meier curves, according to the log-rank test.
The best results for predicting DFS were obtained with 10
TLR features i.e. 2 shape features: Shape_volume and
Shape_centroidDistance; 3 texture matrix-based features:
GLDZM_HIE, GLSZM_SZV and GLDZM_INN; 1 image
intensity: Stats_var; and 4 intensity volume histogram fea-
tures: IVH_RVRI_10, IVH_RVRI_20, IVH_AVRI_80 and
IVH_AVRI_90) selected with the Forward MRMR MI,
discretised with FBN (32 bins) and classified with RF. The
AUC, F1-score 1, F2-score, precision, recall and AUCpr were
Fig. 1 Radiomics pipeline
Table 2 Hazard ratios (HR) with 95% confidence intervals and P
values of clinical features, as well as TV, MTV, SUV Max and TLG
after performing a univariate Cox proportional hazard model to predict
DFS. The Youden Index was used to find a threshold for each predictor,
plot Kaplan-Meier curves and evaluate the performance of each
individual feature in predicting DFS in the test set. AUC, recall,
precision and F1-score were used as DFS performance metrics
P value KM curve F1-score Precision Recall AUC P value in
univariate analysis
HR (95% CI) Feature
0.32 0.33 0.2 1 0.6 0.14 1.23 (0.94–1.6) FIGO
0.15 0.4 0.4 0.4 0.64 0.33 1.14 (0.87–1.5) Histology
0.67 0.22 0.25 0.2 0.54 0.15 1.22 (0.93–1.6) Metastasis
0.027 0.44 0.5 0.4 0.61 0.84 0.97 (0.71–1.3) Age
0.17 0 0 0 0.48 0.01 1.4 (1.1–1.9) TV
0.23 0.36 0.24 0.8 0.48 0.65 1.06 (0.81–1.4) MTV 50%
0.87 0.22 0.15 0.4 0.43 0.1 1.25 (0.96–1.6) SUV MAX
0.67 0.15 0.13 0.2 0.43 0.32 1.14 (0.88–1.5) TLG 50%
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0.72 (0.62–0.8), 0.48 (0.25–0.67), 0.56 (0.22–0.74), 0.40
(0.22–0.60), 0.63 (0.20–0.80) and 0.50 (0.30–0.69), respec-
tively. Adding all clinical data to the TLR features model
further improved the results with AUC, F1-score, F2-score,
precision, recall and AUCpr of 0.78 (0.67–0.88), 0.49
(0.25–0.67), 0.56 (0.22–0.74), 0.42 (0.25–0.60), 0.63 (0.2–
0.80) and 0.53 (0.33–0.72).
Next were the 3 clinical features (age, histology, metasta-
sis) combined with the following 6 radiomic features: one
shape feature (Shape_elongation) and 5 intensity volume his-
togram features, (IVH_RVRI_50, IVH_RVRI_60,
IVH_RVRI_70, IVH_RVRI_80 and IVH_RVRI_90);
discretised using FBW (0.05 SUV), selected with the
Backward MRMR Pearson method and a LR classifier. The
AUC, F1-score, F2-score, precision, recall and AUCpr were
0.65 (0.47–0.73), 0.44 (0.25–0.57), 0.56 (0.32–0.69), 0.32
(0.18–0.44), 0.69 (0.40–0.80) and 0.38 (0.22–0.58), respec-
tively. Adding the remaining clinical feature (FIGO) to the OR
model did not improve prediction performances.
Neither using the ComBat-harmonized features nor apply-
ing ComBat harmonisation on these two models did improve
performances (Supplementary data C).
Figure 3 shows the Kaplan-Meier curves of the best OR
and TLR models, which were significantly discriminant: log-
rank P value of 0.034 for the OR and 0.002 for the TLR
model. Both models performed better than the individual
radiomic features. The differences between AUC and preci-
sion of the OR and TLRmodels were however not statistically
significant (P value = 0.64 and 0.34 respectively).
By randomising the outcome of the test set, we obtain an
AUC of 0.58 for the best ORmodel and anAUC of 0.56 in the
best TLR model.
Training and testing in the independent scanners and on the
external validation scanner resulted in large variations in the
predictive ability of the models. Table 4 illustrates the varia-
tion in the distinct performance metrics for the best OR and
TLR model.
Finally, the radiomic signatures developed by Altazi et al.
did not identify the patients with a higher risk of recurrence in
our population, as shown in Table 5.
Discussion
There are conflicting results regarding the prognostic value of
[18F]FDG uptake in cervical cancer when using conventional
metrics such as the SUVmax, MTV or TLG [8, 9, 41–44]. We
recently found, in a different patient’s sample, TLG to be the
only parameter associated with DFS in multivariate analysis
[45]. In the current multicenter series however, except histol-
ogy, none of the clinical or conventional metabolic features
such as SUV, MTV and TLG were statistically significant
predictors of DFS in univariate analysis. Compared to De
Cuypere et al., the follow-up is slightly shorter in the present
study, but the population size is larger, which consequently
may be statistically more relevant. Moreover, the tumours
were segmented using different methods in the two studies,
which is a factor known to affect the TLG and also radiomic
features reproducibility [46]. Of note, even though the radia-
tion therapy protocols varied across centers, this did not inter-
vene in the DFS. Radiomics has been proposed for
characterising cervical cancer subtypes [47] or predicting the
response to treatment either based upon [18F]FDG PET/CT
alone [8, 11, 48] or in combination with MRI [9] [49, 50]. In
the current series, we confirm that individual radiomic fea-
tures, in particular matrix-based and intensity histogram, are
significant predictors of DFS in uni- and multivariate analysis.
However, the best overall performances are obtained with a
ML model that uses 10 TLR radiomic features characterising
different tumour properties such as shape, texture and intensi-
ty. The best model was obtained when features were selected
using a forward MRMRMI method and classified with a RF.
The good performance of this classifier has been already ob-
served by other studies [20–22]. Furthermore, we found
Table 3 Features which were significant in univariate and multivariate
analysis. For each of the features, we show the hazard ratios (HR) with
95% confidence intervals and P values after performing the univariate
Cox proportional hazard model. Additionally, we also show the AUC,
recall, precision, F1-score and P value of KM curve. The threshold to
measure the last metrics was defined using the Youden index of the
training data set ROC curve. Feature’s names are described as in the
supplementary data B with the additional information of the discretisation
width and features origin (OR or TLR)
P value KM curve F1-
score




HR (95% CI) Feature
0.79 0.21 0.14 0.4 0.46 0.034 0.00049 0.44 (0.28–0.70) GLDZM_DZNN_0.5 (OR)
0.044 0.43 0.28 0.1 0.68 0.0023 0.00058 1.61 (1.20–2.10) GLSZM_HILAE_0.5 (TLR)
0.47 0.13 0.1 0.2 0.43 0.0016 0.001 1.65 (1.20–2.20) GLDZM_DZV_0.05 (TLR
from interpolated images)
0.088 0.24 0.14 0.8 0.61 0.0022 0.001 1.72 (1.20–2.40) Stats_qcod_0.2 (TLR from
interpolated images)
0.15 0.4 0.4 0.4 0.64 NA 0.002 0.65 (0.49–0.85) Histology
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combining clinical and radiomic features improve the predic-
tion ability of the models. Regarding the intensity
discretisation scheme, the application of the FBW
discretisation method in PET has been recommended [15,
29], although some studies have also reported more
favourable properties using FBN [51]. This is related to the
fact that FBN and FBW have different drawbacks and advan-
tages. FBW preserves the relationship between PET units and
the corresponding physical meaning, contrary to arbitrary
units (such as in some non-quantitative MRI sequences).
However, most features cannot be directly compared across
different volumes of interest. FBN on the other hand does not
preserve the relationship between intensities and physical
meaning but introduces a normalisation effect that can be
favourable when contrast is considered important.
Furthermore, it allows direct comparison of values across dif-
ferent volumes of interest. In our findings, the best model was
obtained when using a FBN (32 bins) discretisation method.
We also looked at various parameters known to affect the
reproducibility and robustness of such process. Feature selec-
tion in particular is an important step of the analysis process as
it improves the generalisation of the results. It is known that
each FS method and each classifier has its own limitations,
and indeed, like other researchers in various settings, we did
Fig. 2 Kaplan-Meier curve of the each individual significant feature in
univariate and multivariate analysis, after the Cox proportional hazard
model. a GLDZM_DZNN_0.5 (OR) (Threshold = 0.59, log-rank test P
value 0.079). b GLSZM_HILAE_0.5 (TLR) (Threshold = 0.07, log-rank
test P value 0.044), c GLDZM_DZV_0.05 (TLR from interpolated
images) (Threshold = 1.28, log-rank test P value 0.47). d Stats_qcod_
0.2 (TLR from interpolated images) (Threshold = 1.18, log-rank test P
value 0.088). e Histology (Threshold = 0.5, log-rank test P value 0.15)
Eur J Nucl Med Mol Imaging
observe a large performance variability when using different
methods for discretisation, FS and classification [14–17,
19–22]. In addition, we also evaluated the effect of image
interpolation on the model performances. In radiomics stud-
ies, it is recommended for most textural features to ensure
isotropic voxel sizes across observations or patients.
Isotropic voxel sizes make textural features rotationally invari-
ant, allows direct comparison between the different samples
and improves features reproducibility [29]. However, differ-
ent methods for interpolating images voxels exists, which re-
sult in distinct textural feature values [17] and predictive mod-
el performances [52]. In addition to this, image interpolation
also implies information inference or loss, depending on
whether down-sampling or up-sampling of the voxel size is
performed. In our study, the best radiomics model was obtain-
ed when interpolating images into an isotropic voxel size of
4 × 4 × 4 mm3.
Multi-center radiomics studies imply features variability
mainly due to distinct imaging devices and protocols. This
variability is among the major obstacles preventing generali-
sation of radiomics signatures in the clinical practice.
Different methods have been developed to decrease radiomic
features variability across clinical centers. Harmonising acqui-
sition and reconstruction parameters, for instance through the
EANM EARL initiative might contribute reaching such goal.
A key finding of the present study is that the TLR perform
better across scanners than the native radiomics features. As
each patient acts as his own control, it should not come as a
surprise finding the ratios as more stable than the native fea-
tures. ComBat is another method that was previously success-
fully used for that purpose. It was shown to align features
distributions across different clinical centers as well as to im-
prove predictive ability of radiomic features namely in cervi-
cal cancer DFS prediction [50]. In our dataset, the best model
Fig. 3 Kaplan-Meier curve of the test set for the best OR (a) and TLR (b)
model. Red and blue curves represent respectively patients with better
and worse prognosis. The log-rank test was used to estimate statistical
significance of the difference between survival curves. The P value
obtained from the log-rank test is shown in the left down corner of each
image. The difference between both the Kaplan-Meier curves is statistical
significant (log-rank P value = 0.034 for the OR model and 0.002 for the
TLR model)
Table 4 Variation of Bootstrap mean AUC, F1-score and F2-score,
precision, recall and AUCpr values according to the different test data
obtained from the different scanners. Table 4 (part a) shows the models
usingOR radiomics features and Table 4 (part b) those with TLR features.
The 95% confidence intervals are in parentheses
AUC F1-score F2-score Precision Recall AUCpr
a
Mix Scanner A and B 0.65 (0.47–0.73) 0.44 (0.25–0.57) 0.56 (0.32–0.69) 0.32 (0.18–0.44) 0.69 (0.40–0.80) 0.38 (0.22–0.58)
Scanner A 0.54 (0.24–0.67) 0.37 (0–0.57) 0.46 (0–0.63) 0.29 (0–0.5) 0.55 (0–0.67) 0.36 (0.15–0.72)
Scanner B 0.81 (0.50–1) 0.52 (0.25–0.67) 0.69 (0.36–0.83) 0.37 (0.17–0.50) 0.91 (0.50–1) 0.57 (0.27–1)
Scanner C 0.57 (0.36–0.75) 0.40 (0.14–0.67) 0.35 (0.12–0.61) 0.58 (0.20–1) 0.32 (0.11–0.56) 0.61 (0.46–0.82)
b
Mix Scanner A and B 0.78 (0.67–0.88) 0.49 (0.25–0.67) 0.56 (0.22–0.74) 0.42 (0.25–0.60) 0.63 (0.2–0.8) 0.53 (0.33–0.72)
Scanner A 0.70 (0.56–0.84) 0.36 (0–0.57) 0.41 (0–0.63) 0.31 (0–0.50) 0.46 (0–0.67) 0.39 (0.25–0.65)
Scanner B 0.95 (0.78–1) 0.67 (0.4–1) 0.78 (0.45–1) 0.57 (0.29–1) 0.89 (0.50–1) 0.88 (0.58–1)
Scanner C 0.50 (0.37–0.65) 0.25 (0–0.46) 0.20 (0–0.38) 0.46 (0–0.75) 0.18 (0–0.33) 0.55 (0.46–0.67)
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was not obtained when applying ComBat harmonisation be-
fore FS. Additionally, ComBat did not improve model perfor-
mance when applied after FS in the best OR and TLRmodels.
As observed here, ComBat might therefore not be unequivo-
cally effective, as it presents drawbacks such as the assump-
tion that the site effect follows a Gaussian and Inverse-Gama
distribution and the need for sample sizes large enough to be
statistically representative. Studies have shown in MRI that
ComBat might not preserve biological variability, and minor
differences in pre-processing steps can lead to unexpected
effects during ComBat harmonizsation [53, 54].
There is currently no satisfying answer to the only clinical-
ly relevant question when it comes to introducing ML and
radiomics in the clinical field of nuclear medicine: Is there a
“universal” feature set or ML strategy that could predict the
outcome, in this case DFS in cervical cancer patients, inde-
pendently of the PET/CT device and imaging methodology?.
Indeed, in lung cancer for instance, Parmar et al. [21] and Sun
et al. [19] compared different FS methods and classifiers and
reached very different conclusions. Deist et al. [22] also ob-
served that when training the model with different datasets,
the performance of classifiers is significantly different. We
similarly observed that the performance of our models is high-
ly dependent on the data used to train and test the models,
which can be related to the relatively small sizes of the
datasets, compared to other ML applications where thousands
or tens of thousands of samples are available for training the
models. We also found that the radiomic features or models
selected and developed by other researchers were not trans-
posable to our population i.e. could not predict recurrence in
our patients, with the caveat that the previous works did not
evaluate DFS, but rather LRR [8]. In particular, none of the
parameters selected in the models developed by Altazi et al.
[8] were common to our model, except GLSZM_SZV (size
zone variance from GLSZM matrix, a texture feature) when
used as a ratio with the liver. In Lucia et al. [9]
GLNU_GLRLM was the only PET feature predictive of
DFS, and this parameter was not selected in our models.
Interestingly, this parameter was identified as significant in
Lucia et al. [9], but only when calculated following
discretisation with histogram equalisation, not after FBW or
FBN discretisation. We did not include discretisation with
histograms, as it is currently not included in the IBSI standard.
This illustrates that the devil might indeed be in the details and
further emphasises the need for harmonised feature generation
and robust models across centers and scanners.
Our study presents some limitations. The tumour segmen-
tations were done by a single observer, using the semi-
automatic FLAB algorithm. Using fully automatic and thus
possibly more reproducible segmentation methods [48] [55]
might improve the results, although considering that these
tumours are consistently highly hypermetabolic and easily
delineated, we do not expect major changes. Additionally, it
might also be relevant to evaluate features not only on the
segmented region but also for instance in regions around the
tumour, as proposed by Hao et al. [11]. Finally, in this study,
we dichotomised DFS into a binary outcome and predicted
DFS without considering time-to-event information. Leger
et al. [20] reported that this simplification can bias the models.
However, we believe that this is not clinically relevant since
patients that have a recurrence within a relatively short time,
which is the case in our data, are treated equally. Our results
show that combining distinct radiomics and clinical informa-
tion can help in the stratification of patients with high and low
risks of recurrence. However, the predictive performances of
the metabolic data do not appear good enough to be applied in
clinical practice and need further validation in larger multi-
center cohorts of patients. Further improvements could none-
theless be obtained by combining radiomic features extracted
from other image modalities, such as MRI, as shown by Lucia
et al. [9].
Despite these limitations, to the best of our knowledge, this
is the first study to investigate TLR radiomic features in
predicting DFS in cervical cancer. All the features calculations
were performed using a software which is documented and
fully in line with IBSI standardisation, which should help
other research groups reproduce our results. Our study follows
the TRIPOD guidelines [56] (Supplementary data D) and
scores 42% according to the radiomics quality score, which
compares favourably with the majority of previous radiomics
studies [7]. We believe this is a step towards a possible inte-
gration of radiomics in the clinics, which is slow to come and
hampered by methodological drawbacks, as illustrated by re-
cent articles [57–59].
Future research should include combining different image
modalities [9] [23] and combining features discretised with
different schemes instead of considering each discretisation
set independently. The former is subject to its own inter-
device variability limitations and the latter is more demanding
in terms of computation time. An exhaustive hyper parameter
tuning ofMLmodels could also be investigated for evaluating
the improvement of performance. Fusion or combination of
the different FS and ML techniques could also help in allevi-
ating the variability of resulting models and increase
performance.
Table 5 Radiomic signatures developed by Altazi et al. The models
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Conclusion
In this multicentre series, a ML algorithm with 10 TLR
radiomic features combined with the clinical information re-
sulted in the best predictor of cancer recurrence. Despite these
encouraging results, one cannot ignore the persistence of sig-
nificant dependency of the features on the local acquisition
settings as well as the poor F-score performance. Hence, fur-
ther works need to be done prior to large-scale clinical testing.
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material available at https://doi.org/10.1007/s00259-021-05303-5.
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